Abilify and Remodulin drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Abilify (aripiprazole) and Remodulin (treprostinil sodium). Common drug interactions include headache among females and chest pain among males.

The phase IV clinical study analyzes what interactions people have when they take Abilify and Remodulin. It is created by eHealthMe based on reports of 49 people who take the same drugs from the FDA, and is updated regularly.

What is Abilify?

Abilify has active ingredients of aripiprazole. It is often used in depression. eHealthMe is studying from 101,450 Abilify users. Check the latest studies of Abilify.

What is Remodulin?

Remodulin has active ingredients of treprostinil sodium. It is often used in primary pulmonary hypertension. eHealthMe is studying from 55,842 Remodulin users. Check the latest studies of Remodulin.

On Feb, 11, 2026

49 people who take Abilify and Remodulin together, and have interactions are studied.

Abilify and Remodulin drug interactions.

What are the common drug interactions of Abilify and Remodulin, by gender? *:

female:

Headache (pain in head)
Nausea (feeling of having an urge to vomit)
Dyspnoea (difficult or laboured respiration)
Infusion site erythema (reddening of the skin at infusion site)
Infusion site pain
Infusion site infection
Chest pain
Diarrhoea
Infusion site pruritus (severe itching at infusion site)
Cardiac failure

male:

Chest pain
Death
Diabetes mellitus inadequate control
Disease progression
Ear pain
Glycosuria (excretion of glucose into the urine)
Pancreatitis (inflammation of pancreas)
Pancreatitis acute (sudden inflammation of pancreas)
Pulmonary hypertension (increase in blood pressure in the lung artery)
Type 2 diabetes mellitus

What are the common drug interactions of Abilify and Remodulin, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

Blood cholesterol increased
Blood triglycerides increased
Carpal tunnel syndrome (nerve compression at wrist results numbness weakness, pain , swelling)
Death
Diabetic ketoacidosis (diabetic ketoacidosis (dka) is high concentrations of ketone bodies)
Hyperlipidaemia (presence of excess lipids in the blood)
Insulin resistance
Type 1 diabetes mellitus
Type 2 diabetes mellitus
Weight increased

30-39:

Diarrhoea
Haematemesis (vomiting of blood)
Haemoptysis (blood-stained sputum from the bronchi, larynx, trachea, or lungs)
Nausea (feeling of having an urge to vomit)
Pain
Platelet count decreased
Prerenal failure
Sepsis (a severe blood infection that can lead to organ failure and death)
Therapeutic response decreased (less preventive response)
Vomiting

40-49:

Atelectasis (partial or complete collapse of the lung)
Chest discomfort
Death
Device related infection
Headache (pain in head)
Hypoxia (low oxygen in tissues)
Infusion site infection
Iron deficiency anaemia
Klebsiella bacteraemia (klebsiella bacteria in blood after infection to lungs)
Pleural effusion (water on the lungs)

50-59:

Headache (pain in head)
Nausea (feeling of having an urge to vomit)
Cardiac failure
Dyspnoea (difficult or laboured respiration)
Infusion site erythema (reddening of the skin at infusion site)
Infusion site induration
Infusion site infection
Infusion site pain
Infusion site pruritus (severe itching at infusion site)
Infusion site warmth

60+:

Diverticulitis (digestive disease which involves the formation of pouches (diverticula) within the bowel wall)
Fluid retention (an abnormal accumulation of fluid in the blood)
Tenderness (pain or discomfort when an affected area is touched)
Cellulitis (infection under the skin)
Death
Erythema (redness of the skin)
Malaise (a feeling of general discomfort or uneasiness)
Maternal exposure during pregnancy (use of substance during pregnancy)
Normal newborn
Oedema peripheral (superficial swelling)

What are the existing conditions these people have? *

Pulmonary Hypertension (increase in blood pressure in the lung artery): 6 people, 12.24%
High Blood Pressure: 5 people, 10.20%
Anaemia (lack of blood): 5 people, 10.20%
Allergic Rhinitis: 5 people, 10.20%
Urination - Excessive Volume: 4 people, 8.16%
Joint Pain: 4 people, 8.16%

* Approximation only. Some reports may have incomplete information.

Do you take Abilify and Remodulin?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously